🇺🇸 FDA
Pipeline program

S230815 Solution for injection 10mg/ml

CL1-230815-001

Phase 2 small_molecule active

Quick answer

S230815 Solution for injection 10mg/ml for KCNT1-related Developmental and Epileptic Encephalopathy is a Phase 2 program (small_molecule) at The George Institute with 1 ClinicalTrials.gov record(s).

Program details

Company
The George Institute
Indication
KCNT1-related Developmental and Epileptic Encephalopathy
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials